Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRINOVA-2: Trebananib + PLD in Recurrent Ovarian Cancer
NCT01281254Phase 3Terminated
- Sponsor
- Amgen
- Start
- Apr 2011
- Primary completion
- Aug 2014
- Modality
- Peptides, Antibody-Based Therapeutics, Fc-Fusion Proteins
- Countries
- 18
01
Overview
A Phase 3 trial of trebananib in epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), fallopian tube cancer (PFTC), sponsored by Amgen. Started Apr 2011; status: terminated.
02
Drugs
trebananib
03
Conditions
epithelial ovarian cancer (EOC)primary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT01281254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01281254.